150 related articles for article (PubMed ID: 32499204)
1. Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation.
Berkers G; van der Meer R; van Mourik P; Vonk AM; Kruisselbrink E; Suen SW; Heijerman HG; Majoor CJ; Koppelman GH; Roukema J; Janssens HM; de Rijke YB; Kemper EM; Beekman JM; van der Ent CK; de Jonge HR
J Cyst Fibros; 2020 Nov; 19(6):955-961. PubMed ID: 32499204
[TBL] [Abstract][Full Text] [Related]
2. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
[TBL] [Abstract][Full Text] [Related]
3. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
van de Peppel IP; Doktorova M; Berkers G; de Jonge HR; Houwen RHJ; Verkade HJ; Jonker JW; Bodewes FAJA
J Cyst Fibros; 2019 Mar; 18(2):286-293. PubMed ID: 30279125
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
6. Correlation of sweat chloride and percent predicted FEV
Fidler MC; Beusmans J; Panorchan P; Van Goor F
J Cyst Fibros; 2017 Jan; 16(1):41-44. PubMed ID: 27773592
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
[TBL] [Abstract][Full Text] [Related]
8. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
Rosenfeld M; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Chilvers M; Higgins M; Tian S; Cooke J; Davies JC;
J Cyst Fibros; 2019 Nov; 18(6):838-843. PubMed ID: 31053538
[TBL] [Abstract][Full Text] [Related]
9. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
10. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial.
Davies JC; Wainwright CE; Sawicki GS; Higgins MN; Campbell D; Harris C; Panorchan P; Haseltine E; Tian S; Rosenfeld M
Am J Respir Crit Care Med; 2021 Mar; 203(5):585-593. PubMed ID: 33023304
[No Abstract] [Full Text] [Related]
11. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
13. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
14. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
Walker S; Flume P; McNamara J; Solomon M; Chilvers M; Chmiel J; Harris RS; Haseltine E; Stiles D; Li C; Ahluwalia N; Zhou H; Owen CA; Sawicki G;
J Cyst Fibros; 2019 Sep; 18(5):708-713. PubMed ID: 31253540
[TBL] [Abstract][Full Text] [Related]
15. CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.
Tsabari R; Elyashar HI; Cymberknowh MC; Breuer O; Armoni S; Livnat G; Kerem E; Zangen DH
J Cyst Fibros; 2016 May; 15(3):e25-7. PubMed ID: 26547591
[TBL] [Abstract][Full Text] [Related]
16. The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.
Gostelie R; Stegeman I; Berkers G; Bittermann J; Ligtenberg-van der Drift I; Kipshagen PV; de Winter-de Groot K; Speleman L
PLoS One; 2020; 15(7):e0235638. PubMed ID: 32687499
[TBL] [Abstract][Full Text] [Related]
17. GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).
Davies JC; Van de Steen O; van Koningsbruggen-Rietschel S; Drevinek P; Derichs N; McKone EF; Kanters D; Allamassey L; Namour F; de Kock H; Conrath K
J Cyst Fibros; 2019 Sep; 18(5):693-699. PubMed ID: 31147302
[TBL] [Abstract][Full Text] [Related]
18. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).
van Koningsbruggen-Rietschel S; Conrath K; Fischer R; Sutharsan S; Kempa A; Gleiber W; Schwarz C; Hector A; Van Osselaer N; Pano A; Corveleyn S; Bwirire D; Santermans E; Muller K; Bellaire S; Van de Steen O
J Cyst Fibros; 2020 Mar; 19(2):292-298. PubMed ID: 31594690
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for lumacaftor/ivacaftor clinical response.
Masson A; Schneider-Futschik EK; Baatallah N; Nguyen-Khoa T; Girodon E; Hatton A; Flament T; Le Bourgeois M; Chedevergne F; Bailly C; Kyrilli S; Achimastos D; Hinzpeter A; Edelman A; Sermet-Gaudelus I
J Cyst Fibros; 2019 May; 18(3):368-374. PubMed ID: 30595473
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
